New Options in the Management of Intractable ALK(+) Metastatic Non-Small-Cell Lung Cancer

Lung Cancer: Targets and Therapy - New Zealand
doi 10.2147/lctt.s50414
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Informa UK Limited

Related search

Nivolumab in Metastatic Non–Small Cell Lung Cancer

Journal of the Advanced Practitioner in Oncology
2016English

Brigatinib for ALK-positive Metastatic Non-Small-Cell Lung Cancer: Design, Development and Place in Therapy

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2019English

Tackling ALK in Non-Small Cell Lung Cancer: The Role of Novel Inhibitors

Translational Lung Cancer Research
Oncology
2016English

The Biology and Treatment of EML4-ALK Non-Small Cell Lung Cancer

European Journal of Cancer
Cancer ResearchOncology
2010English

The Treatment Choice Based on Radiographic Features for Metastatic Brain Tumors in ALK-Rearranged Non–small Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2017English

Systematic Review and Meta-Analysis of Selected Toxicities of Approved ALK Inhibitors in Metastatic Non-Small Cell Lung Cancer

Oncotarget
Oncology
2018English

Treating Patients With ALK-positive Non-Small Cell Lung Cancer: Latest Evidence and Management Strategy

Therapeutic Advances in Medical Oncology
Oncology
2015English

Unmet Needs in the Treatment of Metastatic Non-Small-Cell Lung Cancer

European Oncology and Haematology
OncologyHematology
2008English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy